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et al., 2013) shed a light on persistent inﬂammatory process in athero-
sclerosis focusing on pathological humoral immunity between com-
mensal microbes and activated sub-populations of substantial B cell in
the vicinity of arterial adventitia. Because atherosclerosis is becoming
global health burden throughout the world especially in developed
counties, multidisciplinary therapeutic and preventive approachesWehighly appreciate the Commentary by Spence (Spence, 2016) on
our article entitled “Commensal microbes-speciﬁc activation of B2 cell
subsets contribute to atherosclerosis development independent of
lipid metabolism” (Chen et al., in this issue). Atherosclerotic diseases
are systemic disorders and one of the leading causes of mortality and
morbidity throughout the world. Although multiple risk factors, such
as hypertension, diabetes mellitus, hyperlipidemia and smoking, have
been identiﬁed, atherosclerosis is considered to be initiated and
sustained by various metabolic factors (Mihaylova et al., 2012;
Kearney et al., 2008). Previous studies have revealed the pathway
linking dietary food intake, intestinal microﬂora and atherosclerosis.
These studies indicated that increasing the dietary intake of precursors
of toxic metabolic products of the intestinal microbiome, such as the
trimethylamine-N-oxide from phosphatidylcholine and other forms of
choline and carnitine were associated with CVD (Wang et al., 2011;
Koeth et al., 2013; Tang et al., 2013; Spence et al., 2016). Therefore, to
conquer atherosclerotic diseases, appropriate food restrictions accom-
panying appropriatemedical treatment are essential life-stylemodiﬁca-
tion requirement accepted commonly in clinical healthcare guidelines.
Current progress in this area enabled us to recommend the subjects
with high risk in atherosclerosis more targeted food restriction under
speciﬁc diseased conditions including CKD6. Additionally, atherosclero-
sis is considered to arise from an inﬂammatory process. Inﬂammation
associated with atherosclerosis involves complicated processes, includ-
ing systemic inﬂammatory reactions and the accumulation of immune
cells, such asmonocytes/macrophages, dendritic cells, and lymphocytes
(Shimada, 2009). The immune system, encompassing both innate im-
munity and adaptive immunity (cellular immunity and humoral immu-
nity), has been implicated in all stages of atherosclerosis from initiation
through progression, as well as in atherothrombotic complications/j.ebiom.2016.10.030, http://
).
. This is an open access article under(Hansson, 2009). Our current analyses with previous reports (Ishigami
should be expected. In addition in future studies using our model, it
would be of interest to evaluate the effects of both increasing the dietary
intake of precursors of toxic metabolic products of the intestinal
microbiome and abnormally enhanced humoral immunity on the de-
velopment of atherosclerosis. Such effects might act independently of
or perhaps be mediated by the B2-cell effects on atherosclerosis that
we have described.
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